DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Abou-Alfa GK, Chan SL, Furuse J. , et al.
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
J Clin Oncol 2018;
36: TPS4144-TPS4144
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.